Showing papers in "Blood in 2019"

TL;DR: The novel combination of venetoclax with decitabine or azacitidine was effective and well tolerated in elderly patients with AML and achieved complete remission (CR) + CR with incomplete count recovery (CRi).

TL;DR: The characteristic features of these new and modified entities as well as the results of recent molecular studies with diagnostic, prognostic, and/or therapeutic significance for the different types of primary cutaneous lymphomas are reviewed.

TL;DR: Based on experience with anemia treatment in chronic kidney disease, critical illness, and cancer, finding the appropriate indications for the specific treatment of AI will require improved understanding and a balanced consideration of the contribution of anemia to each patient's morbidity and the impact of anemic treatment on the patient's prognosis in a variety of disease settings.

TL;DR: In this article, the authors present expert opinions derived from an interdisciplinary working group on adult HLH, sponsored by the Histiocyte Society, to facilitate knowledge transfer between physicians caring for pediatric and adult patients with HLH with the aim to improve the outcome for adult patients affected by HLH.

TL;DR: It is shown that GM-CSF neutralization with lenzilumab does not inhibit CART19 cell function in vitro or in vivo, and a novel approach to abrogate NI and CRS through GM- CSF neutralized, which may potentially enhance CAR-T cell function.

TL;DR: This review contains specific recommendations for the identification and management of the most important complications such as the bleeding disorder APL differentiation syndrome, QT prolongation, and other all-trans retinoic acid- and ATO-related toxicities.

TL;DR: The role of basic aspects of coagulation and α-thrombin in promoting thromboinflammatory responses is focused on and insights gained from clinical trials on the effects of various inhibitors ofCoagulation on thrombosis with associated inflammation are discussed.

TL;DR: The mechanisms of NET formation are discussed, as well as the apparent paradoxical role of neutrophils and NETs in host defense, chronic inflammation, and tissue disrepair.

TL;DR: This review discusses neutrophil polarization and plasticity and the function of proinflammatory/anti-inflammatory and protumor/antitumor neutrophils in the tumor microenvironment and how neutrophIL with the ability to suppress T-cell activation fit into this paradigm.

TL;DR: Use of a pediatric regimen for AYA patients with newly diagnosed ALL up to age 40 years was feasible and effective, resulting in improved survival rates compared with historical controls, and CALGB 10403 can be considered a new treatment standard upon which to build for improving survival for AYAs with ALL.

TL;DR: Patients with relapsed/refractory B-ALL enrolled in a phase 1/2 clinical trial evaluating lymphodepletion chemotherapy followed by CD19 CAR T-cell therapy who might benefit from consolidation strategies such as allogeneic HCT are studied.

TL;DR: Enasidenib was well tolerated and induced molecular remissions and hematologic responses in patients with AML for whom prior treatments had failed and clearance of mutant-IDH2 clones was also associated with achievement of CR.

TL;DR: There remains a critical need to define the precise temporal and spatial mechanisms by which fibrinogen-directed inflammatory events may dictate the severity of tissue injury and coordinate the remodeling and repair events essential to restore normal organ function.

TL;DR: Zanubrutinib demonstrated encouraging activity in CLL/SLL patients, with a low incidence of major toxicities, and definition of the maximum tolerated dose (part 1).

TL;DR: A phase 2 hypothesis-generating trial to determine whether the addition of the multitargeted kinase inhibitor midostaurin to intensive chemotherapy followed by allogeneic hematopoietic cell transplantation and single-agent maintenance therapy of 12 months is feasible and favorably influences event-free survival (EFS) compared with historical controls.

TL;DR: Results confirmed the effective antitumor activity, durability of response, and manageable safety of pembrolizumab monotherapy in RRcHL, regardless of prior treatment and including chemoresistant cHL.

TL;DR: Emicizumab prophylaxis has been shown to be a highly effective novel medication for children with hemophilia A and inhibitors and two of 88 participants developed antidrug antibodies (ADAs) with neutralizing potential, ie, associated with decreased emicIZumab plasma concentrations.

TL;DR: Investigating whether blocking BCMA cleavage by small molecule γ-secretase inhibitors (GSIs) could augment BCMA-targeted CAR-T cell therapy found that exposure of myeloma cell lines and patient tumor samples to GSIs markedly increased surface BCMA levels in a dose-dependent fashion.

TL;DR: A review of the recent progress in myelodysplastic syndromes (MDS) genetics can be found in this paper, where a comprehensive registry of driver mutations recurrently found in a recognizable fraction of MDS patients has been revealed.

TL;DR: Analysis of clinical and treatment characteristics, serum biomarkers, and CAR T-cell manufacturing and pharmacokinetic data showed that a lower pre-lymphodepletion serum lactate dehydrogenase (LDH) level and a favorable cytokine profile, defined as serum day 0 monocyte chemoattractant protein-1 (MCP-1) and peak interleukin-7 (IL-7) concentrations above the median, were associated with better PFS.

TL;DR: In conclusion, ravulizumab given every 8 weeks achieved noninferiority compared with eculizumAB given every 2 weeks for all efficacy end points, with a similar safety profile.

TL;DR: It was found that lower platelet counts at time of CAR T-cell infusion were associated with more severe neurotoxicity, and high pretreatment lactate dehydrogenase was frequently encountered in lymphoma patients with grade 3-4 neurotoxicity and correlated negatively with progression-free survival.

TL;DR: Patients with PNH may be safely and effectively switched from labeled-dose eculizumab administered every 2 weeks to ravulizumabs administered every 8 weeks, and no meningococcal infections or discontinuations due to adverse events occurred.

TL;DR: Previously-unrecognized evidence is presented that TNF- critically regulates megakaryocytes resident in the bone marrow niche and aging-associated platelet hyperreactivity and thrombosis and age-dependent metabolic profiles that may differentially poise platelets for activation.

TL;DR: The contention that early intervention with the use of tocilizumab and/or corticosteroids in subjects with early signs of CRS is without negative impact on anti-tumor potency of CD19CAR T cells is supported.

TL;DR: The National Marrow Donor Program and the Center for International Blood and Marrow Transplant Research, jointly with the NMDP Histocompatibility Advisory Group, provide evidence-based guidelines for optimal selection of unrelated donors and cord blood units.

TL;DR: This review will focus on recent insights into how the liver senses body iron levels and coordinates this with other signals to regulate hepcidin production and systemic iron homeostasis.

TL;DR: The data supports the safety of CD19-specific CAR T cell therapy for R/R B-ALL and suggest that dose intensity of conditioning chemotherapy and minimal pre-treatment disease burden have a positive impact on response without a negative effect on toxicity.

TL;DR: An institutional experience with 8 secondary CNS lymphoma patients treated with commercial tisagenlecleucel shows no patient experienced >grade 1 neurotoxicity and no patient required tocilizumab or steroids for CAR-T mediated toxicities.

TL;DR: Long-term follow-up of patients treated in RESONATE provides support for sustained efficacy and safety of ibrutinib in relapsed/refractory CLL and consideration of study provisions that allow crossover to investigational therapy when benefit has been clearly demonstrated.